Cargando…
Review on molnupiravir as a promising oral drug for the treatment of COVID-19
During the COVID-19 pandemic, various drug candidates have been developed, molnupiravir (MK-4482 and EIDD-2801), which is a new orally anti-viral agent under development for the treatment of COVID-19, is under study in the final stage of the clinical trial. Molnupiravir enhances the replication of v...
Autores principales: | Zarenezhad, Elham, Marzi, Mahrokh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721938/ https://www.ncbi.nlm.nih.gov/pubmed/35002192 http://dx.doi.org/10.1007/s00044-021-02841-3 |
Ejemplares similares
-
Paxlovid: Mechanism of Action, Synthesis, and In Silico Study
por: Marzi, Mahrokh, et al.
Publicado: (2022) -
Comprehensive review on molnupiravir in COVID-19: a novel promising antiviral to combat the pandemic
por: Khiali, Sajad, et al.
Publicado: (2022) -
Applications of Metallic Nanoparticles in the Skin Cancer Treatment
por: Marzi, Mahrokh, et al.
Publicado: (2022) -
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
por: Jayk Bernal, Angélica, et al.
Publicado: (2021) -
Bilosomes as Nanocarriers for the Drug and Vaccine Delivery against Gastrointestinal Infections: Opportunities and Challenges
por: Zarenezhad, Elham, et al.
Publicado: (2023)